Advanced Filters
noise

Additional Locations, Massachusetts Clinical Trials

A listing of Additional Locations, Massachusetts clinical trials actively recruiting patient volunteers.

Found 1,878 clinical trials
B Barbara McDonough, RN

Congenital Heart Disease GEnetic NEtwork Study (CHD GENES)

Congenital heart defects (CHD) are the most common major human birth malformation, affecting ~8 per 1,000 live births. CHD are associated with significant morbidity and mortality, and are second only to infectious diseases in contributing to the infant mortality rate. Current understanding of the etiology of pediatric cardiovascular disorders is …

- 99 years of age All Phase N/A
S Study Coordinator

The Molecular Basis of Inherited Reproductive Disorders

The goal of this study is to learn more about the genes that control puberty and reproduction in humans.

1 years of age All Phase N/A
O Olivia Balderes

Kidney Precision Medicine Project

Acute kidney injury (AKI) and chronic kidney disease (CKD) impose a significant global health burden. Yet, no effective therapies currently exist for AKI, and only a few are available for CKD. Despite significant effort from industry and academia, development of pharmacologic therapies for AKI and CKD has been hampered by: …

18 years of age All Phase N/A
G Grace Addy

Intermuscular Coherence as a Biomarker for ALS

The specific aims of this study are to: Determine if a painless and quick measurement of muscle activity using surface electrodes can help with the diagnosis of ALS. Specifically, we ask if a measure of intermuscular coherence (IMC-βγ), when added to current diagnostic criteria (Awaji criteria), can differentiate ALS from …

20 - 90 years of age All Phase N/A
R Rachel Unger

Rare and Atypical Diabetes Network

RADIANT is a network of 14 clinical sites and several laboratories dedicated to the study of atypical diabetes. The objective of this study is to define new forms of diabetes and the unique mechanisms underlying these forms of atypical diabetes. The specific aims are to: Identify and enroll individuals and …

years of age All Phase N/A
M Miriam Evans, PhD

Triage Survey for Psychiatry Research Eligibility

TRIAGE-Psych is a survey study designed to assess potential participants' eligibility to screen for industry-sponsored psychiatry clinical trials.

18 years of age All Phase N/A
T Tonette Gehrking

Natural History Study of Synucleinopathies

Synucleinopathies are a group of rare diseases associated with worsening neurological deficits and the abnormal accumulation of the protein α-synuclein in the nervous system. Onset is usually in late adulthood at age 50 or older. Usually, synucleinopathies present clinically with slowness of movement, coordination difficulties or mild cognitive impairment. Development …

18 years of age All Phase N/A
A Amir Shaban, MD

Stroke Thrombectomy and Aneurysm Registry

This international multi-center registry is used to collect existing information and outcomes for patients undergoing an operation for treatment of injuries to the brain including the blockage of blood flow to an area of the brain, an abnormal ballooning of an artery, abnormal tangling of blood vessels, abnormal formation of …

1 - 120 years of age All Phase N/A

Go Fit Fast, Recovery Trajectory Using PROMIS®, Linking PROMIS®

Prospective data will be collected in approximately 3500 patients (700 per 5 injury groups). Patients will be followed up according to the standard (routine) for up to 1 year after the treatment. Data collection will include underlying disease, treatment details, patient reported outcomes (PROs), anticipated or procedure-related adverse events (i.e. …

18 years of age All Phase N/A
I Irene Ghobrial, MD

Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)

The PROMISE Study aims to establish a prospective cohort of individuals with precursor conditions to multiple myeloma, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). We will study these patients as a means to identify risk factors for progression to symptomatic multiple myeloma.

30 years of age All Phase N/A

Simplify language using AI